New weight loss pill approved for use in UK

The FDA has approved a daily weight-loss pill developed by Eli Lilly for use in the UK, marking the first European country to do so. The medication, named Foundayo, is aimed at treating obesity and type 2 diabetes. While Foundayo can be purchased privately with a prescription, its availability on the NHS has yet to be determined by the Medicines and Healthcare products Regulatory Agency.

Foundayo belongs to the class of GLP-1 medications, which work by reducing appetite. It follows the MHRA's approval of a pill version of a similar weight-loss drug, Wegovy, in June. Eli Lilly stated that the pill could be immediately used by the NHS for treating type 2 diabetes, but it plans to apply to the National Institute for Health and Care Excellence in England for approval as a weight loss treatment.

Dr. Simon Cork from Anglia Ruskin University noted that Foundayo's weight-loss effects are less pronounced than other treatments, but patients could still expect clinically meaningful weight changes. He also highlighted that Foundayo is likely to be more affordable than other weight-loss treatments, which are often restricted by the NHS.

Prof Naveed Sattar from the University of Glasgow echoed the positive aspects of Foundayo, mentioning its convenience compared to Wegovy, which must be taken on an empty stomach. Sattar believes the arrival of another effective oral weight-loss option will help more people access treatment tailored to their needs and preferences.

Clinical trials showed that patients who used weight-loss injections and then started taking Foundayo daily for a year maintained most of their weight loss, a common challenge with GLP-1 injections. Individuals on weight-loss medication are advised to maintain a healthy diet and exercise routine. Like all medications, Foundayo may cause side effects such as nausea, diarrhea, constipation, and vomiting.